EPA Invites Clinicians to answer the TRUSTING Survey on Psychotic Relapse Risk
The EPA invites clinicians to take part in the TRUSTING Survey for Evaluating Risk of Relapse, launched today, Monday, 9 February.
Clinicians practising in English, Czech, Dutch, French, German, or Turkish are kindly encouraged to answer this survey aiming to better understand how relapse risk in psychosis is identified in current clinical practice, in order to inform the development of a complementary, remote monitoring tool. The survey takes approximately 15 minutes to complete and focuses on the routines used by clinicians and clinical teams to detect relapse risk in individuals with psychosis. Participation is entirely voluntary and anonymous.
Clinicians Survey Patients Survey
Clinicians who share their knowledge will play a key role in shaping a user-friendly, research-informed, and trustworthy AI application designed to support the prediction of psychotic relapse. The EPA is proud to collaborate with GAMIAN-Europe and other TRUSTING partners on a project that actively brings patients and clinicians together to shape research and innovation for future mental healthcare.
The TRUSTING Project
Psychotic disorders often follow a fluctuating course, with individuals remaining vulnerable to relapse, particularly when antipsychotic medication is reduced or discontinued. When warning signs are identified early, psychotic relapses can often be prevented through timely interventions such as reinstatement of medication, psychotherapy, social support, or a combination of approaches. Accurate and timely detection can therefore make a substantial difference to outcomes and quality of life.
The TRUSTING project is based on the hypothesis that spontaneous speech may hold critical information for predicting imminent psychotic relapse. Within the project, individuals at risk of relapse will be invited to record short speech samples at regular intervals using a secure, private remote digital environment. Using artificial intelligence methods, these speech samples will be analysed to detect subtle changes that may indicate emerging psychotic symptoms, such as hallucinations, delusions, or thought disorder.
The main goal of the project is to develop a trustworthy, easy-to-use AI-based monitoring application that can be used from home and delivers alerts when speech deviations predictive of relapse are detected. Such a tool has the potential to support people vulnerable to psychosis in living more independently, reducing fear of relapse, with or without long-term antipsychotic maintenance treatment.
TRUSTING has three overarching objectives: to create an accurate speech-based predictor of psychotic relapse that is validated across languages, speech tasks, and clinical subgroups; to build a trustworthy speech-based AI monitoring tool for relapse prediction and test its effectiveness in a randomised controlled trial; and to evaluate the cost-effectiveness of the AI monitoring tool while defining a protection and commercialisation roadmap.
The TRUSTING User Board
The TRUSTING Clinicians User Board, coordinated by the EPA, consists of nine clinicians with expertise in the treatment of schizophrenia and psychotic disorders. The group provides expert advice to the TRUSTING consortium and plays a key role in ensuring that the project’s tools and methods are clinically relevant, feasible, and aligned with real-world practice. In parallel, the TRUSTING Patients User Board, coordinated by GAMIAN-Europe, ensures that the perspectives, needs, and priorities of people with lived experience of psychosis are fully integrated into the project’s design and implementation.
Clinicians User Board Patients User Board
Together, these groups embody the consortium’s commitment to co-creation, ensuring that innovation in mental health is grounded in both clinical expertise and lived experience.
